Clonidine
- PMID: 29083638
- Bookshelf ID: NBK459124
Clonidine
Excerpt
Clonidine is a central alpha-2 adrenergic and imidazoline receptor agonist that lowers blood pressure and heart rate by decreasing sympathetic outflow, leading to vasodilation and improved myocardial perfusion. Clonidine holds Food and Drug Administration–approved indications beyond antihypertensive therapy, including treatment of attention-deficit/hyperactivity disorder in children, management of tics associated with Tourette syndrome, and adjunctive therapy for severe cancer-related pain. This activity reviews the mechanism of action, indications, adverse event profile, toxicity, dosing, drug interactions, and monitoring of clonidine, providing a comprehensive understanding of its pharmacology. Mastery of these aspects enables healthcare professionals to individualize treatment plans, optimize therapeutic outcomes, and minimize adverse events, ensuring safe and effective use of clonidine in diverse patient populations.
Copyright © 2025, StatPearls Publishing LLC.
Conflict of interest statement
Sections
References
-
- Tian Z, Vollmer Barbosa C, Lang H, Bauersachs J, Melk A, Schmidt BMW. Efficacy of pharmacological and interventional treatment for resistant hypertension: a network meta-analysis. Cardiovasc Res. 2024 Feb 27;120(1):108-119. - PubMed
-
- Groom MJ, Cortese S. Current Pharmacological Treatments for ADHD. Curr Top Behav Neurosci. 2022;57:19-50. - PubMed
-
- Wolraich ML, Hagan JF, Allan C, Chan E, Davison D, Earls M, Evans SW, Flinn SK, Froehlich T, Frost J, Holbrook JR, Lehmann CU, Lessin HR, Okechukwu K, Pierce KL, Winner JD, Zurhellen W, SUBCOMMITTEE ON CHILDREN AND ADOLESCENTS WITH ATTENTION-DEFICIT/HYPERACTIVE DISORDER Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents. Pediatrics. 2019 Oct;144(4) - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources